These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 510836

  • 1. FDA begins proceedings to remove erythromycin estolate from market.
    FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836
    [No Abstract] [Full Text] [Related]

  • 2. Ilosone update.
    Culp ER.
    Am Fam Physician; 1980 Apr; 21(4):23. PubMed ID: 7377065
    [No Abstract] [Full Text] [Related]

  • 3. Risk-benefit equation for erythromycin estolate.
    LeBel M.
    Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788
    [No Abstract] [Full Text] [Related]

  • 4. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver.
    Gafter U, Mandel EM, Weiss S, Djaldetti M.
    N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477
    [No Abstract] [Full Text] [Related]

  • 5. [Cholestatic hepatitis caused by erythromycin estolate].
    García Monzón C, Noguerado A, Hidalgo S, Escudero V.
    Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470
    [No Abstract] [Full Text] [Related]

  • 6. Erythromycin estolate to remain on market.
    FDA Drug Bull; 1982 Aug; 12(2):14. PubMed ID: 7141171
    [No Abstract] [Full Text] [Related]

  • 7. [Hepatitis caused by various derivatives of erythromycin].
    Funck-Brentano C, Pessayre D, Benhamou JP.
    Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792
    [No Abstract] [Full Text] [Related]

  • 8. Erythromycin propionate and estolate.
    Farre M.
    Lancet; 1988 Jul 02; 2(8601):45. PubMed ID: 2898648
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Selection of an oral erythromycin product.
    Fraser DG.
    Am J Hosp Pharm; 1980 Sep 02; 37(9):1199-205. PubMed ID: 6998290
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Erythromycin-induced hepatitis].
    Perrier M, Portier G, de Calan L, Favre JP, Ozoux JP, Rivallain B, Brizon J.
    Cah Anesthesiol; 1987 Sep 02; 35(3):237. PubMed ID: 3621021
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Erythromycin].
    Simmen HP, Siegenthaler W, Lüthy R.
    Dtsch Med Wochenschr; 1982 Oct 01; 107(39):1480-2. PubMed ID: 7117164
    [No Abstract] [Full Text] [Related]

  • 16. [Hepatotoxicity from erythromycin estolate].
    Saiz Santos S, Montero López L.
    Aten Primaria; 1992 Dec 01; 10(9):1050. PubMed ID: 1467424
    [No Abstract] [Full Text] [Related]

  • 17. Erythromycin hepatotoxicity. A rare cause of a false-positive technetium-99m DISIDA study.
    Swayne LC, Kolc J.
    Clin Nucl Med; 1986 Jan 01; 11(1):10-2. PubMed ID: 3943237
    [Abstract] [Full Text] [Related]

  • 18. Case study: Drug interference in clinical chemistry.
    Hansen JL, Swanson LN.
    Am J Med Technol; 1981 Mar 01; 47(3):189-91. PubMed ID: 7223765
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.